Moderna is poised to surge another 45% in the next year, COVID-19 vaccine could generate more than $5 billion in annual sales, Jefferies says (MRNA)

Moderna is poised to surge another 45% in the next year, COVID-19 vaccine could generate more than $5 billion in annual sales, Jefferies says (MRNA)

Business Insider

Published

· *On Monday, Jefferies initiated coverage of Moderna with a "buy" rating and a price target of $90 on the potential that the pharmaceutical company's COVID-19 vaccine is approved. *
· *That represents 45% upside from where shares of Moderna closed on Friday. *
· *Jefferies also thinks that if the COVID-19 vaccine is...

Full Article